Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis.

Authors: Makino, Y  Noguchi, E  Takahashi, N  Matsumoto, Y  Kubo, S  Yamada, T  Imoto, Y  Ito, Y  Osawa, Y  Shibasaki, M  Uchida, K  Meno, K  Suzuki, H  Okubo, K  Arinami, T  Fujieda, S 
Citation: Makino Y, etal., J Allergy Clin Immunol. 2010 Dec;126(6):1163-9.e5.
Pubmed: (View Article at PubMed) PMID:20810159
DOI: Full-text: DOI:10.1016/j.jaci.2010.06.031

BACKGROUND: Allergic rhinitis is a global health problem that causes major illnesses and disability worldwide. Allergen-specific immunotherapy (SIT) is the only available treatment that can alter the natural course of allergic disease. However, the precise mechanism underlying allergen-SIT is not well understood. OBJECTIVE: The aim of the current study was to identify protein expression signatures reflective of allergen-SIT-more specifically, sublingual immunotherapy (SLIT). METHODS: Serum was taken twice from patients with seasonal allergic rhinitis caused by Japanese cedar: once before the pollen season and once during the season. A total of 25 patients was randomly categorized into a placebo-treated group and an active-treatment group. Their serum protein profiles were analyzed by 2-dimensional electrophoresis. RESULTS: Sixteen proteins were found to be differentially expressed during the pollen season. Among the differentially expressed proteins, the serum levels of complement C4A, apolipoprotein A-IV (apoA-IV), and transthyretin were significantly increased in SLIT-treated patients but not in placebo-treated patients. Among these proteins, the serum levels of apoA-IV correlated with the clinical symptom-medication scores (r = -0.635; P < .05) and with quality of life scores (r = -0.516; P < .05) in the case of SLIT-treated patients. The amount of histamine released from the basophils in vitro was greatly reduced after the addition of recombinant apoA-IV in the medium (P < .01). CONCLUSION: Our data will increase the understanding of the mechanism of SLIT and may provide novel insights into the treatment of allergic rhinitis.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 5685642
Created: 2012-01-13
Species: All species
Last Modified: 2012-01-13
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.